Meanwhile, I am leading the effort in Congress to lower drug prices and create competition, allowing you to choose something better.
Lead efforts to lower drug prices and create competition in health care.
Occurrences
Cassidy said Congress can lower prescription drug costs by increasing competition among generic and biosimilar manufacturers and that he is spearheading an agenda to make health care affordable.
This discussion draft proposes commonsense solutions to improve 340B for patients, ensuring the Program lowers costs for American families.
Evidence
Cassidy said, "To lower the cost of drugs we need to increase competition," and announced a package of three bills focused on reducing drug prices by getting generics to market faster, including REMEDY, biosimilars, and generic-access legislation.
Cassidy said the Ensuring Innovation Act would help lower prescription drug prices by preventing unjustified exclusivity that delays cheaper generics from entering the market; the release says the bill was signed into law by the president.
The HELP Committee release says several Cassidy-led provisions were signed into law to lower prescription drug prices, and that the package "corrects misaligned incentives" used by pharmacy benefit managers and ensures discounts are passed through to lower patient costs.
The HELP Committee said the Senate passed provisions to lower prescription drug prices and rein in health care middlemen, describing them as "directly in line with President Trump's priorities to make health care affordable for families."
Cassidy said Congress can lower prescription drug costs by increasing competition among generic and biosimilar manufacturers and that he is spearheading an agenda to make health care affordable.
Assessments
Cassidy repeatedly advanced legislation and committee action aimed at lowering drug prices and increasing competition, and at least one Cassidy-led drug-price measure was signed into law in 2021. Later HELP Committee actions in 2026 further support continued leadership, but the core promise was already fulfilled through enacted federal policy during his Senate service.
Cassidy materially advanced the promised outcome through federal legislative work aimed at lowering prescription drug prices by increasing competition, including generic and biosimilar access measures. His competition-focused package was introduced during the term that began after the 2014 campaign, and Cassidy-led legislation was later signed into law, including the Ensuring Innovation Act in April 2021 and later drug-pricing/PBM provisions in 2026. Because the enacted outcomes occurred after the initial 2015-2021 Senate term tied to the 2014 campaign, the promise counts as delivered with later_term timing rather than same_term.